文献速递白血病造血干细胞移植与细胞治疗

序贯使用贝林妥欧单抗与奥英妥珠单抗治疗后复发的B细胞急性淋巴细胞白血病患者的结局

Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab.
PubMed 文献 · Blood Adv · 2022-01-01

该研究报告29例既往接受过贝林妥欧单抗和奥英妥珠单抗治疗的复发/难治性B细胞急性淋巴细胞白血病患者结局:25例(86.2%)以贝林妥欧单抗为第一种单克隆抗体,44%出现CD19阴性/弱阳性复发;奥英妥珠单抗对贝林妥欧单抗后复发者诱导完全缓解率68%,不受CD19表达状态影响;获缓解后19例中12例(63.2%)接受异基因造血干细胞移植,但总体生存差。

要点

  • 贝林妥欧单抗后复发者中44%出现CD19阴性/弱阳性复发
  • 奥英妥珠单抗对贝林妥欧单抗后复发诱导完全缓解率68%,与CD19表达状态无关
  • 两种单克隆抗体后复发患者属超高危组,总体生存差

核心结论

  • 贝林妥欧单抗后复发的B-ALL患者可被奥英妥珠单抗成功挽救并桥接至alloHSCT,但该群体属超高危组,总体生存差。
  • 原文结论提出包括新型巩固治疗和治疗顺序的进一步研究可能改善这些患者的结局。

研究设计与样本

  • 报告29例既往接受过贝林妥欧单抗和奥英妥珠单抗治疗的复发/难治性B细胞急性淋巴细胞白血病患者的结局。
  • 25例(86.2%)以贝林妥欧单抗作为第一种单克隆抗体(mAb1)。
  • 第一种与第二种单克隆抗体(mAb1至mAb2)的中位间隔为99天。

主要发现

  • 贝林妥欧单抗后复发者中44%观察到CD19阴性/弱阳性复发。
  • 奥英妥珠单抗对贝林妥欧单抗后复发者诱导完全缓解率为68%,不受CD19表达状态影响。
  • mAb2后达到缓解的19例中12例(63.2%)接受alloHSCT,mAb2至alloHSCT中位时间37.5天。
  • 急性移植物抗宿主病发生率为58.3%(3级或以上25%),非复发死亡率为41.7%。
  • mAb2后中位随访16.8个月,19例(65.5%)复发,21例(72.4%)死亡;alloHSCT与非alloHSCT患者总体生存无差异。

局限性

  • 原文结论提出需进一步研究包括新型巩固治疗和治疗顺序以改善这些患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel monoclonal antibody (mAb)-based therapies targeting CD19 and CD22 (blinatumomab and inotuzumab) have shown high rates of complete remission (CR) and been used as a bridging treatment to potentially curative allogeneic hematopoietic stem cell transplantation (alloHSCT) in adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, limited data exist on the outcome of patients resistant to both mAbs as well as responses to each agent when progressed after the alternate antigen-targeted mAb. Herein, we report outcomes of 29 patients with R/R B-ALL previously treated with both blinatumomab and inotuzumab. Twenty-five patients (86.2%) received blinatumomab as first mAb (mAb1), and CD19-negative/dim relapses were observed in 44% of the patients. Inotuzumab induced CR in 68% of the patients for post-blinatumomab relapse regardless of CD19 expression status. The median time between mAb1 and mAb2 was 99 days. Twelve (63.2%) of 19 patients who achieved remission after mAb2 underwent alloHSCT. The median time from mAb2 to alloHSCT was 37.5 days. Acute graft-versus-host disease and nonrelapse mortality were observed in 58.3% (grade 3 or higher, 25%) and 41.7%, respectively. With a median follow-up of 16.8 months after mAb2, 19 patients (65.5%) relapsed, and 21 patients (72.4%) have died. Overall survival was not different between alloHSCT and non-alloHSCT patients. In conclusion, patients with B-ALL who relapsed after blinatumomab could be successfully rescued by inotuzumab as a bridge to alloHSCT but represent an ultra-high-risk group with poor overall survival. Further studies, including novel consolidation and treatment sequence, may improve outcomes of these patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wudhikarn K, King AC, Geyer MB, et al. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. Blood Adv. 2022. PMID: 35042232. doi:10.1182/bloodadvances.2021005978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。